

Clinical implications of discrepancies in predicting pediatric mortality between Pediatric Index of Mortality 3 and Pediatric Logistic Organ Dysfunction-2

Eui Jun Lee¹, Bongjin Lee², You Sun Kim³, Yu Hyeon Choi⁴, Young Ho Kwak¹, June Dong Park^{2,5}

Departments of ¹Emergency Medicine and ²Pediatrics, Seoul National University College of Medicine, Seoul; ³Department of Pediatrics, National Medical Center, Seoul; ⁴Department of Pediatrics, Hanyang University Medical Center, Seoul; ⁵Wide River Institute of Immunology, Seoul National University, Hongcheon, Korea

Background: Pediatric Index of Mortality 3 (PIM 3) and Pediatric Logistic Organ Dysfunction-2 (PELOD-2) are validated tools for predicting mortality in children. Research suggests that these tools may have different predictive performance depending on patient group characteristics. Therefore, we designed this study to identify the factors that make the mortality rates predicted by the tools different.

Methods: This retrospective study included patients (<18 years) who were admitted to a pediatric intensive care unit from July 2017 to May 2019. After defining the predicted mortality of PIM 3 minus the predicted mortality rate of PELOD-2 as "difference in mortality prediction," the clinical characteristics significantly related to this were analyzed using multivariable regression analysis. Predictive performance was analyzed through the Hosmer-Lemeshow test and area under the receiver operating characteristic curve (AUROC).

Results: In total, 945 patients (median [interquartile range] age, 3.0 [0.0–8.0] years; girls, 44.7%) were analyzed. The Hosmer-Lemeshow test revealed AUROCs of 0.889 ($\chi^2=10.187$, $P=0.313$) and 0.731 ($\chi^2=6.220$, $P=0.183$) of PIM 3 and PELOD-2, respectively. Multivariable linear regression analysis revealed that oxygen saturation, partial pressure of CO₂, base excess, platelet counts, and blood urea nitrogen levels were significant factors. Patient condition-related factors such as cardiac bypass surgery, seizures, cardiomyopathy or myocarditis, necrotizing enterocolitis, cardiac arrest, leukemia or lymphoma after the first induction, bone marrow transplantation, and liver failure were significantly related ($P<0.001$).

Conclusions: Both tools predicted observed mortality well; however, caution is needed in interpretation as they may show different prediction results in relation to specific clinical characteristics.

Key Words: child; intensive care unit; mortality; severity of illness index

INTRODUCTION

Predicting mortality is very important in the process of caring for critically ill patients. Depending on the likelihood of mortality, the urgency of the use of medical resources can be assessed, and the medical condition can be detected and treated early before progression [1-3].

Original Article

Received: October 18, 2021

Revised: February 21, 2022

Accepted: March 5, 2022

Corresponding author

Bongjin Lee

Department of Pediatrics, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea

Tel: +82-2-2072-3568

Fax: +82-2-2072-0274

E-mail: pedbjl@snu.ac.kr

Copyright © 2022 The Korean Society of Critical Care Medicine

This is an Open Access article distributed under the terms of Creative Commons Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

There are various tools for predicting mortality in critically ill pediatric patients, among which Pediatric Index of Mortality 3 (PIM 3) and Pediatric Logistic Organ Dysfunction-2 (PELOD-2) are widely used worldwide [4,5]. The predictive performance and effectiveness of both prediction tools have been proven through several validation studies [6-9].

However, in a retrospective study of children who received bone marrow transplantation, it was reported that there was no significant difference in mortality predicted by PIM (previous version of PIM 3) between survivors and non-survivors [10]. Another study of patients undergoing surgery for congenital heart disease reported a weak relationship between the severity of the patient's condition and the PELOD (previous version of PELOD-2) score [11]. Since it is important to be aware that the performance of a mortality prediction system may vary according to a specific disease or patient group, we attempted to find studies on PIM 3 and/or PELOD-2, which are the upgraded versions of PIM and PELOD, respectively. However, to the best of our knowledge, none of the available studies exactly fit this purpose. Therefore, we designed this study with the aim of determining whether there are patient group characteristics that influence the mortality predictive performance of PIM 3 and PELOD-2, and if any, we aimed to determine the specific factors that cause the difference in performance between these tools.

MATERIALS AND METHODS

Study Setting

This retrospective observational study was conducted at a 24-bed medical and surgical pediatric intensive care unit (PICU) of a tertiary hospital. Patients under the age of 18 years who were admitted to the PICU from July 2017 to May 2019 were included, and patients with vital signs that were considered non-physiologic were excluded from the analysis. The non-physiologic vital signs were defined as: heart rate (HR) above 300 beats/min or below 30 beats/min, respiratory rate (RR) above 120 breaths/min or below 5 breaths/min, body temperature above 42°C or below 30°C, and oxygen saturation below 30%.

Data Collection and Pre-processing

The following data were collected from the hospital's electronic health records: age; sex; physical findings such as blood pressure (BP), HR, and RR; clinical findings such as vasoactive-inotropic scores and the use of mechanical ventilation;

KEY MESSAGES

- The predictive performance of both Pediatric Index of Mortality 3 and Pediatric Logistic Organ Dysfunction-2 is good.
- There is a difference in performance between the tools based on patient characteristics and groups.

and laboratory findings such as blood gas analysis results and electrolyte levels. Among these variables, BP, HR, and RR, whose normal ranges change with age [12], were not used in order to avoid age-related bias, but the z-score for each variable was calculated and used for analyses. In the process of calculating the z-score, the “generalized additive models for location scale and shape” and “sitar” package of R software (R Foundation for Statistical Computing, Vienna, Austria) were used [13,14]. The PIM 3 and PELOD-2 scores were calculated using formulas presented in the development studies [4,5]. When calculating the scores of the above tools, the worst one was used within 1 hour of entering the PICU, and the results of the examination within 1 hour of entering the PICU were used based on the examination execution time, not the examination result report time. The process of recording data through the hospital information system was performed by one researcher, and the PIM 3 and PELOD-2 scores were calculated through R coding.

Outcome Measures

The primary outcome in this study was an analysis of factors affecting the mortality prediction performance of PIM 3 and PELOD-2. For this, the value obtained by subtracting the predicted mortality rate of PELOD-2 from the predicted mortality rate of PIM 3 was defined as “difference in mortality prediction”, and related factors were analyzed using multivariable linear regression. The secondary outcome was whether there was a difference from observed mortality in each subgroup; this was obtained by performing subgroup analysis on categorical variables among factors that were significantly related to “difference in mortality prediction” in the multivariable analysis.

Statistical Analysis

To analyze the relationship between the mortality predicted by PIM 3 or PELOD-2 and the observed mortality, the area under the receiver operating characteristic curve (AUROC) and Hosmer-Lemeshow goodness of fit test were used, and the grade

was set to 10 steps. Linear regression analyses were used to analyze factors related to the “difference in mortality prediction,” and factors that showed significant results in the univariable analyses were used to create a multivariable linear regression model. The final model was derived using the backward selection method. All statistical analyses were performed using R version 4.0.3 (R Foundation for Statistical Computing), and $P < 0.05$ were considered statistically significant.

Ethics Statements

The need for obtaining ethics approval of the study protocol and written consent from the study participants was waived by the Institutional Review Board of the institution where this study was conducted (H-2004-229-1119).

RESULTS

Baseline Characteristics

During the study period, a total of 1,073 patients were screened, and 945 patients were finally analyzed after applying the inclusion and exclusion criteria (Figure 1). The median (interquartile range) age was 3.0 years (0.0–8.0 years), and 44.7% of the patients were girls. Table 1 provides detailed information regarding the baseline characteristics. The Hosmer-Lemeshow goodness of fit test was conducted to confirm whether the mortality predicted by the severity scoring tools differed from the observed mortality. The results of PIM 3 (AUROC=0.889, $\chi^2=10.187$, $P=0.313$) showed no statistically significant difference from the observed mortality. The results of PELOD-2 were also AUROC=0.731, $\chi^2=6.220$, $P=0.183$, showing that there was no difference from the observed mortality. Both PIM 3 and PELOD-2 showed fair to good predictive performance in predicting the observed mortality (Figure 2).




Figure 1. Study flow diagram.

Main Outcomes

Based on the multivariable analysis, oxygen saturation ($\beta = -0.065$, standard error [SE]=0.012, $P < 0.001$), base excess ($\beta = -0.124$, SE=0.024, $P < 0.001$), a diagnosis of seizures ($\beta = -3.598$, SE=0.723, $P < 0.001$), and cardiac bypass surgery ($\beta = -2.083$, SE=0.264, $P < 0.001$) were associated with a decrease in the “difference in mortality prediction” between the tools. That is, the mortality rate predicted by PELOD-2 tends to increase to a greater extent than the mortality rate predicted by PIM 3 as the factors correspond to the above variables. In contrast, partial pressure of CO₂ ($\beta = 0.041$, SE=0.010, $P < 0.001$); platelet counts ($\beta = 0.004$, SE=0.001, $P < 0.001$); blood urea nitrogen levels ($\beta = 0.045$, SE=0.017, $P = 0.008$); diagnoses of cardiomyopathy or myocarditis ($\beta = 3.810$, SE=0.948, $P < 0.001$), necrotizing enterocolitis ($\beta = 4.356$, SE=1.356, $P < 0.001$), cardiac arrest ($\beta = 20.691$, SE=0.813, $P < 0.001$), and leukemia or lymphoma after the first induction ($\beta = 9.066$, SE=2.163, $P < 0.001$); bone marrow transplantation ($\beta = 6.255$, SE=1.542, $P < 0.001$); and liver failure ($\beta = 5.907$, SE=1.257, $P < 0.001$) were associated with an increase in the “difference in mortality prediction” (the more the above factors were met, the higher the predicted mortality rate of PIM 3 was that of PELOD-2) (Table 2).

Table 3 shows the results of the subgroup analyses based




Figure 2. The receiver operating characteristic (ROC) curves according to situations of observed mortality and predicted mortality by Pediatric Index of Mortality 3 (PIM 3) and Pediatric Logistic Organ Dysfunction-2 (PELOD-2). P-values were derived using the Hosmer-Lemeshow goodness of fit test. AUROC: area under the ROC curve.

Table 1. Demographic and baseline characteristics of the participants

Variable	Value (n=945)
Age (yr)	3.0 (0.0 to 8.0)
Female	422 (44.7)
Length of stay in ICU (hr)	24.2 (19.0 to 77.7)
Underlying disease	
Cardiovascular disease	138 (13.3)
Endocrinologic disease	48 (4.6)
Gastrointestinal disease	84 (8.1)
Genetic disease	108 (10.4)
Genitourinary disease	62 (6)
Hemato-oncologic disease	174 (16.8)
Infectious disease	42 (4.1)
Neuromuscular disease	171 (16.5)
Ophthalmologic disease	27 (2.6)
Psychologic disease	38 (3.7)
Respiratory disease	119 (11.5)
Trauma	25 (2.4)
Physical finding	
Z-score of SBP by age	0.0 (-0.7 to 0.7)
Z-score of DBP by age	-0.0 (-0.7 to 0.6)
Z-score of MBP by age	0.0 (-0.6 to 0.6)
Z-score of HR by age	0.0 (-0.7 to 0.7)
Z-score of RR by age	0.0 (-0.7 to 0.7)
Body temperature (°C)	36.8 (36.3 to 37.2)
Oxygen saturation (%)	99.0 (95.0 to 100.0)
Glasgow coma scale	
Eye	4.0 (4.0 to 4.0)
Verbal	5.0 (5.0 to 5.0)
Motor	6.0 (6.0 to 6.0)
Fixed pupil reflex, both	14 (1.5)
Clinical finding	
Vasoactive-inotropic score	0.0 (0.0-3.2)
Mechanical ventilation application	696 (73.7)
Laboratory finding	
pH	7.4 (7.3 to 7.4)
Partial pressure of CO ₂ (mm Hg)	41.0 (36.0 to 47.0)
Total CO ₂ (mmol/L)	24.0 (21.5 to 27.2)
Base excess (mmol/L)	-0.8 (-3.5 to 1.4)
Leukocyte (×10 ³ cells/μl)	9.4 (5.6 to 13.9)
Platelet (×10 ³ cells/μl)	192.0 (106.0 to 282.0)
Glucose (mg/dl)	115.0 (87.0 to 156.0)
Potassium (mg/dl)	4.0 (3.6 to 4.4)
Lactate (mmol/L)	1.5 (0.9 to 2.5)
BUN (mg/dl)	8.0 (5.0 to 10.0)
Creatinine (mg/dl)	0.3 (0.1 to 0.4)
Bilirubin (mg/dl)	0.6 (0.3 to 1.0)
PT-INR	1.2 (1.1 to 1.3)
aPTT (sec)	34.7 (29.9 to 42.0)
Elective admission to ICU ^a	773 (81.8)

Variable	Value (n=945)
Association between ICU admission and surgery ^a	
Not related to surgery	200 (21.2)
Bypass cardiac surgery	209 (22.1)
Non-bypass cardiac surgery	44 (4.7)
Non-cardiac surgery	492 (52.1)
Low-risk diagnosis ^a	
None	909 (96.2)
Bronchiolitis	4 (0.4)
Diabetic ketoacidosis	6 (0.6)
Seizure	26 (2.8)
High-risk diagnosis ^a	
None	908 (96.1)
Spontaneous cerebral hemorrhage	12 (1.3)
Cardiomyopathy or myocarditis	15 (1.6)
Hypoplastic left heart syndrome	1 (0.1)
Neurodegenerative disorder	3 (0.3)
Necrotizing enterocolitis	6 (0.6)
Very high-risk diagnosis ^a	
None	913 (96.6)
Cardiac arrest	15 (1.6)
Severe combined immune deficiency	2 (0.2)
Leukemia or lymphoma after first induction	3 (0.3)
Bone marrow transplant recipient	6 (0.6)
Liver failure	6 (0.6)
Predicted mortality rate by PIM 3	2.0 (0.9 to 2.7)
Predicted mortality rate by PELOD-2	0.9 (0.5 to 1.4)
Observed all-cause ICU mortality	17 (1.8)

Values are presented as median (interquartile range) or number (%).

ICU: intensive care unit; SBP: systolic blood pressure; DBP: diastolic BP; MBP: mean BP; HR: heart rate; RR: respiratory rate; BUN: blood urea nitrogen; PT-INR: prothrombin time international normalized ratio; aPTT: activated partial thromboplastin time; PIM 3: Pediatric Index of Mortality 3; PELOD-2: Pediatric Logistic Organ Dysfunction-2.

^aFor this classification, the criteria of the PIM 3 calculation formula were used [4].

on categorical variables among the factors confirmed to affect “difference in mortality prediction” in the multivariable analysis. Similar to the results of the multivariable analysis, PELOD-2 had a higher predictive mortality rate than PIM 3 in cases of bypass cardiac surgery or seizures, and PIM 3 had a higher predictive mortality rate in other cases. In the Hosmer-Lemeshow goodness of fit test result, only the predicted mortality of PIM 3 could be analyzed in both ‘cardiomyopathy or myocarditis’ and ‘cardiac arrest’ cases, and none of them showed a statistically significant difference; thus, PIM 3 predicted the actual observed mortality well in the subgroup (Table 3).

Table 2. Demographics and baseline variables on linear regression analysis

Variable	Univariable analysis			Multivariable analysis		
	Estimate	SE	P-value	Estimate	SE	P-value
Age (yr)	0.059	0.031	0.055			
Sex						
Male	Reference					
Female	-0.466	0.310	0.133			
Physical finding						
Z-score of SBP by age	0.247	0.155	0.113			
Z-score of HR by age	0.140	0.154	0.364			
Z-score of RR by age	0.142	0.155	0.359			
Body temperature (°C)	0.075	0.192	0.696			
Oxygen saturation (%)	-0.091	0.015	<0.001	-0.065	0.012	<0.001
Glasgow coma scale						
Eye	0.700	0.183	<0.001			
Verbal	0.407	0.121	0.001			
Motor	0.718	0.143	<0.001			
Fixed pupil reflex	0.948	1.277	0.458			
Clinical finding						
Vasoactive-inotropic score	-0.006	0.008	0.410			
Mechanical ventilation						
No	Reference					
Yes	0.672	0.350	0.055			
Laboratory finding						
pH	-15.690	1.656	<0.001			
Partial pressure of CO ₂ (mm Hg)	0.082	0.014	<0.001	0.041	0.010	<0.001
Total CO ₂ (mmol/L)	-0.028	0.032	0.372			
Base excess (mmol/L)	-0.223	0.035	<0.001	-0.124	0.024	<0.001
Leukocyte (×10 ³ cells/μl)	0.053	0.021	0.013			
Platelet (×10 ³ cells/μl)	0.005	0.001	<0.001	0.004	0.001	<0.001
Glucose (mg/dl)	0.000	0.002	0.786			
Potassium (mg/dl)	0.266	0.124	0.033			
Lactate (mmol/L)	0.435	0.089	<0.001			
BUN (mg/dl)	0.081	0.020	<0.001	0.045	0.017	0.008
Creatinine (mg/dl)	0.377	0.295	0.202			
Bilirubin (mg/dl)	0.114	0.096	0.234			
PT	0.070	0.024	0.004			
PT-INR	1.588	0.436	<0.001			
aPTT (sec)	-0.002	0.009	0.808			
Elective admission to ICU ^a						
No	Reference					
Yes	-2.825	0.389	<0.001			
Association between ICU admission and surgery ^a						
Not related to surgery	Reference			Reference		
Bypass cardiac surgery	-2.786	0.361	<0.001	-2.083	0.264	<0.001
Non-bypass cardiac surgery	1.908	0.730	0.009			
Non-cardiac surgery	0.018	0.309	0.955			

(Continued to the next page)

Table 2. Continued

Variable	Univariable analysis			Multivariable analysis		
	Estimate	SE	P-value	Estimate	SE	P-value
Low-risk diagnosis						
None	Reference			Reference		
Bronchiolitis	-3.210	2.375	0.177			
Diabetic ketoacidosis	-2.215	1.942	0.254			
Seizure	-2.998	0.938	0.001	-3.598	0.723	<0.001
High-risk diagnosis						
None	Reference			Reference		
Spontaneous cerebral hemorrhage	2.024	1.377	0.142			
Cardiomyopathy or myocarditis	3.281	1.230	0.008	3.810	0.948	<0.001
Hypoplastic left heart syndrome	0.654	4.747	0.891			
Neurodegenerative disorder	0.934	2.743	0.733			
Necrotizing enterocolitis	5.547	1.935	0.004	4.356	1.356	0.001
Very high-risk diagnosis						
None	Reference			Reference		
Cardiac arrest	23.157	0.978	<0.001	20.691	0.813	<0.001
Severe combined immune deficiency	4.838	3.355	0.150			
Leukemia or lymphoma after first induction	6.826	2.734	0.013	9.066	2.163	<0.001
Bone marrow transplant recipient	6.635	1.931	0.001	6.255	1.542	<0.001
Liver failure	5.937	1.933	0.002	5.907	1.257	<0.001

SE: standard error; SBP: systolic blood pressure; HR: heart rate; RR: respiratory rate; BUN: blood urea nitrogen; PT-INR: prothrombin time international normalized ratio; aPTT: activated partial thromboplastin time; ICU: intensive care unit.

^aFor this classification, the criteria of the Pediatric Index of Mortality 3 (PIM 3) calculation formula were used [4].

Table 3. Subgroup analysis of factors related to the difference in predicted mortality between PIM 3 and PELOD-2

Variable	No. of patients	Observed mortality	PIM 3				PELOD-2			
			Predicted mortality rate	AUROC	χ ²	P-value	Predicted mortality rate	AUROC	χ ²	P-value
Bypass cardiac surgery	209	0	0.7 (0.6–0.9)	NA	NA	NA	0.9 (0.5–1.4)	NA	NA	NA
Seizure	26	0	0.4 (0.2–0.6)	NA	NA	NA	1.1 (0.5–3.5)	NA	NA	NA
Cardiomyopathy or myocarditis	15	1 (0.1)	4.4 (3.0–5.9)	0.929	1.243	0.996	0.9 (0.3–2.2)	NA	NA	NA
Necrotizing enterocolitis	6	0	7.6 (6.5–10.3)	NA	NA	NA	0.7 (0.5–1.4)	NA	NA	NA
Cardiac arrest	15	3 (20.0)	22.0 (18.2–35.1)	0.639	11.809	0.160	3.5 (1.1–3.5)	NA	NA	NA
Leukemia or lymphoma after first induction	3	2 (66.7)	6.2 (3.5–13.8)	NA	NA	NA	1.4 (1.1–1.4)	NA	NA	NA
Bone marrow transplant recipient	6	1 (16.7)	8.6 (6.0–10.1)	NA	NA	NA	0.9 (0.5–2.2)	NA	NA	NA
Liver failure	6	1 (16.7)	9.2 (8.6–9.6)	NA	NA	NA	1.5 (0.5–3.5)	NA	NA	NA

Values are presented as number (%) or median (interquartile range).

PIM 3: Pediatric Index of Mortality 3; PELOD-2: Pediatric Logistic Organ Dysfunction-2; AUROC: area under the receiver operating characteristic curve; NA: not applicable.

DISCUSSION

We conducted this study to determine whether there may be a difference in the predictive performance between PIM 3 and PELOD-2. Further, we investigated the specific factors that cause the difference. We found that both PIM 3 and PELOD-2 showed good performance in predicting the observed mortality;

however, both showed slightly different results in predicting mortality according to the clinical characteristics of the patients.

Previous studies reported that the AUROC range of PIM 3 was 0.75–0.88 [8,15–19]. The AUROC of PELOD-2 was reported to be in the range of 0.75 to 0.94 [7,17–20]. In our results, the AUROC values of PIM 3 and PELOD-2 were 0.889 and 0.731,

respectively, which were not significantly different from those in previous studies.

In this study, the “difference in mortality prediction” was affected by several factors, suggesting that the predicted mortality rates of PIM 3 and PELOD-2 may be affected by the characteristics of the patient group. As mentioned earlier, there is no existing study comparing PIM 3 and PELOD-2 according to patient group characteristics; thus, it was impossible to directly compare the results of our study with those in the existing literature. However, we were able to find one published paper suggesting that PELOD-2 scores may be lower in certain patient groups [20]. That study is a prospective observational study of critically ill children who needed plasma transfusion admitted to 101 PICUs in 21 countries. It was reported that the mortality prediction of PELOD-2 showed a fair performance, i.e., an AU-ROC of 0.76, but a relatively low predictive power compared to previous results, i.e., an AUROC of 0.934. In addition, the study concluded that the predictive power of PELOD-2 may be different in specific subpopulations [21]. Although plasma transfusion itself was not analyzed as a relevant factor in our study, PELOD-2 showed a lower mortality rate than PIM 3 in patients with leukemia, bone marrow transplantation, and liver failure who were expected to require large amounts of plasma transfusion. Of course, these results cannot be directly applied; however, we believe it might be a worthwhile point considering the relevance to existing studies conducted in patients who received plasma transfusions.

In the subgroup analysis results, most observed mortality was closer to the predicted mortality of PIM 3 than the predicted mortality of PELOD-2. However, we did not think that this was a result that meant that PIM 3 was superior to PELOD-2. This is because, while targeting a specific subpopulation, the sample size corresponding to each subgroup was very small (e.g., only three patients in the case of leukemia or lymphoma after first induction). Additionally, since this subgroup analysis is binary based on whether the listed factors are or not, there may be other potential confounding factors in each subgroup. Further, as a result of the Hosmer-Lemeshow test, most of the items were not applicable. The test was designed to compare the predicted mortality rate range (from 0% to 100%) with mortality by dividing it into 10 segments with 10% intervals. Therefore, it was difficult to derive results from the small sample population by dividing it into several subgroups.

This study has several limitations. First, this was a single center study. Thus, there may be differences in the results when the tools are applied in other institutions. However, we

attempted to include a sufficiently large number of participants in our study. Second, the timing at which each tool was applied may have been different for individual patients. This is because the calculation definitions of PIM 3 and PELOD-2 are different, and our study was performed within a defined calculation time range. Third, the sample size was relatively insufficient to perform subgroup analysis. Finally, it was thought that clinical management before ICU admission might have been different for each patient, but it is not considered to be the focus of the study itself.

Both PIM 3 and PELOD-2 showed good results in predicting mortality but showed different predictive results depending on the specific clinical characteristics of the patient. Since the study was conducted at a single center and contained a relatively insufficient sample size, it may be difficult to directly apply the results of this study to other institutions. Therefore, it is necessary to supplement these results with multicenter studies including sufficient sample sizes in the future. Moreover, when applying and interpreting the above tools in clinical practice based on these results, it is necessary to consider the characteristics of each individual patient.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Eui Jun Lee	https://orcid.org/0000-0002-6304-8277
Bongjin Lee	https://orcid.org/0000-0001-7878-9644
You Sun Kim	https://orcid.org/0000-0002-7687-2687
Yu Hyeon Choi	https://orcid.org/0000-0002-3057-0886
Young Ho Kwak	https://orcid.org/0000-0003-2062-7575
June Dong Park	https://orcid.org/0000-0001-8113-1384

AUTHOR CONTRIBUTIONS

Conceptualization: BL. Data curation: BL, YSK, YHC. Formal analysis: EJL, BL. Methodology: EJL, BL. Project administration: BL. Visualization: EJL, BL. Writing—original draft: EJL. Writing—review & editing: BL, YSK, YHC, YHK, JDP.

REFERENCES

1. Wolfler A, Osello R, Gualino J, Calderini E, Vigna G, Santuz P, et

- al. The importance of mortality risk assessment: validation of the Pediatric Index of Mortality 3 score. *Pediatr Crit Care Med* 2016;17:251-6.
2. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to treatment and mortality during mandated emergency care for sepsis. *N Engl J Med* 2017;376:2235-44.
 3. Khwannimit B, Bhurayanontachai R, Vattanavanit V. Comparison of the accuracy of three early warning scores with SOFA score for predicting mortality in adult sepsis and septic shock patients admitted to intensive care unit. *Heart Lung* 2019;48:240-4.
 4. Straney L, Clements A, Parslow RC, Pearson G, Shann F, Alexander J, et al. Paediatric Index of Mortality 3: an updated model for predicting mortality in pediatric intensive care. *Pediatr Crit Care Med* 2013;14:673-81.
 5. Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F, et al. PELOD-2: an update of the Pediatric logistic organ dysfunction score. *Crit Care Med* 2013;41:1761-73.
 6. Schlapbach LJ, Straney L, Bellomo R, MacLaren G, Pilcher D. Prognostic accuracy of age-adapted SOFA, SIRS, PELOD-2, and qSOFA for in-hospital mortality among children with suspected infection admitted to the intensive care unit. *Intensive Care Med* 2018;44:179-88.
 7. El-Nawawy A, Mohsen AA, Abdel-Malik M, Taman SO. Performance of the pediatric logistic organ dysfunction (PELOD) and (PELOD-2) scores in a pediatric intensive care unit of a developing country. *Eur J Pediatr* 2017;176:849-55.
 8. Sankar J, Gulla KM, Kumar UV, Lodha R, Kabra SK. Comparison of outcomes using Pediatric Index of Mortality (PIM)-3 and PIM-2 models in a pediatric intensive care unit. *Indian Pediatr* 2018;55:972-4.
 9. Lee OJ, Jung M, Kim M, Yang HK, Cho J. Validation of the Pediatric Index of Mortality 3 in a single pediatric intensive care unit in Korea. *J Korean Med Sci* 2017;32:365-70.
 10. Jacobe SJ, Hassan A, Veys P, Mok Q. Outcome of children requiring admission to an intensive care unit after bone marrow transplantation. *Crit Care Med* 2003;31:1299-305.
 11. Russell RA, Ghanayem NS, Kuhn EM, Jeffries HE, Scanlon MC, Rice TB. Relationship between risk-adjustment tools and the pediatric logistic organ dysfunction score. *World J Pediatr Congenit Heart Surg* 2014;5:16-21.
 12. Fleming S, Thompson M, Stevens R, Heneghan C, Plüddemann A, Maconochie I, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. *Lancet* 2011;377:1011-8.
 13. Stasinopoulos DM, Rigby RA. Generalized additive models for location scale and shape (GAMLSS) in R. *J Stat Softw* 2008;23:1-46.
 14. Cole TJ, Donaldson MD, Ben-Shlomo Y. SITAR: a useful instrument for growth curve analysis. *Int J Epidemiol* 2010;39:1558-66.
 15. Arias López MD, Boada N, Fernández A, Fernández AL, Ratto ME, Siaba Serrate A, et al. Performance of the Pediatric Index of Mortality 3 score in PICUs in Argentina: a prospective, national multicenter study. *Pediatr Crit Care Med* 2018;19:e653-61.
 16. Jung JH, Sol IS, Kim MJ, Kim YH, Kim KW, Sohn MH. Validation of Pediatric Index of Mortality 3 for predicting mortality among patients admitted to a pediatric intensive care unit. *Acute Crit Care* 2018;33:170-7.
 17. Niederwanger C, Varga T, Hell T, Stuerzel D, Prem J, Gassner M, et al. Comparison of pediatric scoring systems for mortality in septic patients and the impact of missing information on their predictive power: a retrospective analysis. *PeerJ* 2020;8:e9993.
 18. Ramazani J, Hosseini M. Comparison of the predictive ability of the pediatric risk of mortality iii, pediatric index of mortality3, and pediatric logistic organ dysfunction-2 in medical and surgical intensive care units. *J Compr Ped* 2019;10:e82830.
 19. Wong JJ, Hornik CP, Mok YH, Loh TF, Lee JH. Performance of the Paediatric Index of Mortality 3 and Paediatric Logistic Organ Dysfunction 2 scores in critically ill children. *Ann Acad Med Singap* 2018;47:285-90.
 20. Gonçalves JP, Severo M, Rocha C, Jardim J, Mota T, Ribeiro A. Performance of PRISM III and PELOD-2 scores in a pediatric intensive care unit. *Eur J Pediatr* 2015;174:1305-10.
 21. Karam O, Demaret P, Duhamel A, Shefler A, Spinella PC, Stanworth SJ, et al. Performance of the Pediatric Logistic Organ Dysfunction-2 score in critically ill children requiring plasma transfusions. *Ann Intensive Care* 2016;6:98.